Atractylodin Suppresses TGF-β-Mediated Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells and Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
| dc.contributor.author | Chang, Kai-Wei | en |
| dc.contributor.author | Zhang, Xiang | en |
| dc.contributor.author | Lin, Shih-Chao | en |
| dc.contributor.author | Lin, Yu-Chao | en |
| dc.contributor.author | Li, Chia-Hsiang | en |
| dc.contributor.author | Akhrymuk, Ivan V. | en |
| dc.contributor.author | Lin, Sheng-Hao | en |
| dc.contributor.author | Lin, Chi-Chien | en |
| dc.date.accessioned | 2021-10-22T14:13:26Z | en |
| dc.date.available | 2021-10-22T14:13:26Z | en |
| dc.date.issued | 2021-10-15 | en |
| dc.date.updated | 2021-10-22T13:56:04Z | en |
| dc.description.abstract | Idiopathic pulmonary fibrosis (IPF) is characterized by fibrotic change in alveolar epithelial cells and leads to the irreversible deterioration of pulmonary function. Transforming growth factor-beta 1 (TGF-β1)-induced epithelial-mesenchymal transition (EMT) in type 2 lung epithelial cells contributes to excessive collagen deposition and plays an important role in IPF. Atractylodin (ATL) is a kind of herbal medicine that has been proven to protect intestinal inflammation and attenuate acute lung injury. Our study aimed to determine whether EMT played a crucial role in the pathogenesis of pulmonary fibrosis and whether EMT can be utilized as a therapeutic target by ATL treatment to mitigate IPF. To address this topic, we took two steps to investigate: 1. Utilization of anin vitro EMT model by treating alveolar epithelial cells (A549 cells) with TGF-β1 followed by ATL treatment for elucidating the underlying pathways, including Smad2/3 hyperphosphorylation, mitogen-activated protein kinase (MAPK) pathway overexpression, Snail and Slug upregulation, and loss of E-cadherin. Utilization of an in vivo lung injury model by treating bleomycin on mice followed by ATL treatment to demonstrate the therapeutic effectiveness, such as, less collagen deposition and lower E-cadherin expression. In conclusion, ATL attenuates TGF-β1-induced EMT in A549 cells and bleomycin-induced pulmonary fibrosis in mice. | en |
| dc.description.version | Published version | en |
| dc.format.mimetype | application/pdf | en |
| dc.identifier.citation | Chang, K.-W.; Zhang, X.; Lin, S.-C.; Lin, Y.-C.; Li, C.-H.; Akhrymuk, I.; Lin, S.-H.; Lin, C.-C. Atractylodin Suppresses TGF-β-Mediated Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells and Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice. Int. J. Mol. Sci. 2021, 22, 11152. | en |
| dc.identifier.doi | https://doi.org/10.3390/ijms222011152 | en |
| dc.identifier.uri | http://hdl.handle.net/10919/105639 | en |
| dc.language.iso | en | en |
| dc.publisher | MDPI | en |
| dc.rights | Creative Commons Attribution 4.0 International | en |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en |
| dc.subject | idiopathic pulmonary fibrosis | en |
| dc.subject | transforming growth factor-beta 1 | en |
| dc.subject | epithelial-mesenchymal transition | en |
| dc.subject | atractylodin | en |
| dc.subject | Smad2/3 | en |
| dc.subject | MAPK | en |
| dc.title | Atractylodin Suppresses TGF-β-Mediated Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells and Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice | en |
| dc.title.serial | International Journal of Molecular Science | en |
| dc.type | Article - Refereed | en |
| dc.type.dcmitype | Text | en |